




Healthcare Industry News: GSK
News Release - March 13, 2007
GlaxoSmithKline Announces Expansion of Patient Assistance Program to Include TYKERB(R)
PHILADELPHIA, March 13 (HSMN NewsFeed) -- GlaxoSmithKline (NYSE: GSK ) has confirmed that its new treatment TYKERBŪ (lapatinib) will be available through Commitment to Access, the company's program that provides low income patients with access to GSK products used in an outpatient setting in the United States.For patients enrolled in a Medicare Part D plan, eligibility also requires documentation of $600 in expenditures on prescription medicines in the current calendar year. Patients who are eligible for Medicare and who have incomes below 135 percent of the federal poverty level may not be eligible for GSK's patient assistance programs if they qualify for full assistance under Medicare.
More information regarding Commitment to Access is available at www.CommitmentToAccess.com and by calling 1-866-475-3678.
About GlaxoSmithKline
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For more than twenty years, GlaxoSmithKline and its predecessor companies have provided assistance to those who need help in getting their medicines. Last year, GSK provided nearly 402,000 patients more than $370 million in free medicines through its patient assistance programs that benefit low income patients of all ages. For company information, visit GlaxoSmithKline at http://www.GSK.com.
Inquiries: US Media Inquiries: Sarah Alspach +1 919 483 2839
Mary Anne Rhyne +1 919 483 2839
(1) Alaska: $85,600/household of two; Hawaii: $78,560/household of two. United States Department of Health and Human Services, 2007 HHS Poverty Guidelines. Available online at http://aspe.hhs.gov/poverty/07poverty.shtml.
Source: GlaxoSmithKline
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.